Clinical trials: Extensive Stage Lung Small Cell Carcinoma
Carcinoma, Small Cell Lung
Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer
This multicenter phase II trial is designed to study the unique combination of chemotherapy (irinotecan./carboplatin) and bevacizumab in the extensive-stage setting.
- Trial name
- NCT00294931
- Testing
- irinotecan, carboplatin, bevacizumab
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- SCRI Development Innovations, LLC
Small Cell Lung Cancer
Carboplatin and Etoposide in Combination With Vorinostat for Patients With Extensive Stage Small Cell Lung Cancer
The Phase I portion of the study is to assess the maximum tolerated dose of vorinostat when combined with carboplatin plus etoposide.
- Trial name
- NCT00702962
- Testing
- Vorinostat, Carboplatin, Etoposide
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Milton S. Hershey Medical Center
Extensive Small Cell Lung Cancer
A Phase II Clinical Study of Cadonilimab in Treatment-naïve or Relapsed Extensive Small Cell Lung Cancer
Small cell lung cancer (SCLC) accounts for 15% of lung cancer cases and is an aggressive cancer characterized by rapid growth, early metastasis, and a poor prognosis.
- Trial name
- NCT06406673
- Testing
- Cadonilimab+EC/ET+RT, Cadonilimab+vorolanib
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Henan Cancer Hospital
SCLC, Extensive Stage
Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide
Small cell lung cancer (SCLC) is a rapidly proliferating, neuroendocrine tumor that accounts for about 15% of all lung cancers. Most patients have metastases at primary diagnosis involving sites like bone, adrenal glands, liver…
- Trial name
- SPACE (NCT04221529)
- Testing
- Atezolizumab
- Where
- 19 sites in Austria, Germany
- Volunteers
- 70 people
- Sponsor
- AIO-Studien-gGmbH
Small Cell Lung Cancer
Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction
To evaluate the efficacy and safety of liposome irinotecan combined with platinum and immune checkpoint inhibitor combined with antirotinib maintenance therapy after first-line induction
- Trial name
- NCT06951841
- Testing
- Liposome Irinotecan, Platinum, Tislelizumab
- Where
- China
- Volunteers
- 31 people
- Sponsor
- China Medical University, China
Lung Cancer, Metastatic Cancer
11C Topotecan PET Imaging
RATIONALE: Diagnostic procedures, such as positron emission tomography (PET scan) using 11C topotecan, may help doctors predict a patient's response to treatment and help plan the best treatment.
- Conditions
- Lung Cancer, Metastatic Cancer, Ovarian Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00253461
- Testing
- computed tomography, positron emission tomography, 11C topotecan
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Case Comprehensive Cancer Center
Small-cell Lung Cancer
Phase II Trial of Consolidative Thoracic Radiotherapy for ES-SCLC After Standard Care of Chemo-immunotherapy
This is an open-label, single arm Phase II study designed to evaluate the efficacy and safety of thoracic radiotherapy for extensive-stage small-cell lung cancer treated with PD-1/PD-L1 plus etoposide platinum followed by…
- Trial name
- NCT05552846
- Testing
- thoracic radiotherapy
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Ruijin Hospital